In a significant milestone for electrophysiology, Medtronic has unveiled compelling real-world data confirming the safety and efficacy of its next-generation cardiac ablation portfolio. The findings, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, center on two flagship innovations: the PulseSelect Pulsed Field Ablation (PFA) system and the Affera mapping and ablation system, utilized in conjunction with the Sphere-9 catheter.
As the prevalence of atrial fibrillation (AFib) and complex ventricular arrhythmias continues to rise globally, these prospective registry studies offer clinicians critical insights into how these sophisticated technologies perform outside the controlled environment of traditional clinical trials, providing a clear roadmap for the future of cardiac intervention.
The Core Data: A New Benchmark for Safety and Efficacy
The research presented at APHRS 2026 represents a massive scale of clinical observation. By aggregating data from over 2,200 patients across international centers, Medtronic has provided a comprehensive overview of how their latest ablation tools handle the rigors of daily clinical practice.
The REAL PULSE Prospective Study
The REAL PULSE study focused on the PulseSelect PFA system, a technology designed to simplify pulmonary vein isolation (PVI) through a single-shot delivery mechanism. PFA has become the focal point of modern electrophysiology due to its tissue-selective properties, which theoretically minimize damage to surrounding anatomical structures.
In this study, clinicians evaluated 1,160 AFib patients across 38 international centers. The results were striking: the analysis reported a 100% acute success rate for the procedure. Furthermore, the acute major complication rate was recorded at a remarkably low 0.09%, a figure that sets a high bar for procedural safety in the field of cardiac electrophysiology.
The APEX Registry Findings
While REAL PULSE showcased the PFA system, the APEX prospective registry provided a deep dive into the versatility of the Affera mapping and ablation system paired with the Sphere-9 catheter. The Sphere-9 is distinct in its ability to combine high-definition mapping with both radiofrequency and pulsed field energy, allowing for a more tailored approach to complex ablations.
In a cohort of 1,050 AFib patients treated across 28 global sites, investigators recorded a major complication rate of just 1.1%. Notably, the study highlighted a complete absence of severe coronary spasm, acute kidney injury, or phrenic nerve injury—complications that have historically been associated with traditional thermal ablation techniques. Perhaps most importantly, the data revealed no significant variance in complication rates between initial ablation procedures and repeat interventions, suggesting that the system maintains a stable safety profile regardless of the patient’s procedural history.
Chronology: From Innovation to Real-World Validation
The journey of these technologies from development to the APHRS 2026 stage reflects Medtronic’s long-term strategy to dominate the electrophysiology market through iterative, data-driven innovation.
- Initial Development Phase: Medtronic’s acquisition of Affera was a strategic move to integrate high-definition mapping with versatile energy delivery. The Sphere-9 catheter was designed to address the "gap" in existing technologies that often required multiple catheters for mapping and ablation.
- Regulatory and Clinical Trials: Following successful early-stage trials, both PulseSelect and the Affera system underwent rigorous testing to ensure they met international regulatory standards for safety and performance.
- The REAL PULSE and APEX Launch: These registries were designed to capture the "post-market" reality. By moving beyond the highly selected populations of randomized controlled trials (RCTs), Medtronic aimed to show that their technology works effectively in the hands of a broad spectrum of clinicians, from academic medical centers to community hospitals.
- APHRS 2026 Presentation: The presentation of this data marks the transition of these systems into the standard of care for many institutions, as the industry begins to view PFA and high-definition mapping as the "gold standard" for managing cardiac arrhythmias.
Supporting Data: Expanding into Ventricular Tachycardia (VT)
While AFib remains the most common arrhythmia treated via ablation, the management of ventricular tachycardia (VT) represents a more significant clinical challenge due to the structural complexity of the heart and the severity of the patient population.
A specific sub-study within the APEX registry examined 46 individuals undergoing catheter ablation for sustained ischaemic and non-ischaemic VT. Utilizing the Sphere-9 catheter, the cohort demonstrated an acute success rate of 87%. More impressively, the estimated six-month freedom from arrhythmia recurrence stood at 75%.
The data provided a nuanced look at the efficacy of these tools in patients with underlying heart disease. The study found that long-term freedom from recurrent VT did not differ significantly between patients with ischaemic cardiomyopathy (often caused by prior heart attacks) and those with non-ischaemic cardiomyopathy. This consistency is vital for clinicians who need reliable performance across diverse patient profiles. While four patients in this cohort experienced major complications, the overall performance of the system in these high-risk cases suggests a promising new tool for patients who previously had limited therapeutic options.
Official Perspectives: The Leadership View
Khaldoun Tarakji, Medtronic’s vice-president and chief of electrophysiology therapies (science, research, and technology), underscored the significance of these findings during the APHRS proceedings.
"These favourable results reinforce our confidence in the safety and performance of our ablation technologies worldwide," Tarakji stated. He emphasized that the transition from theory to real-world practice is the most critical hurdle for any medical device. "It is very encouraging to see physicians’ positive response and real-world evidence that supports effective, safe, and efficient care for patients with a wide range of arrhythmias."
Tarakji’s comments highlight a shift in industry philosophy: moving away from marketing claims based on laboratory performance and toward evidence-based confidence built on the actual experiences of frontline clinicians.
Implications: The Future of Electrophysiology
The implications of the REAL PULSE and APEX findings are profound for the medical device sector and, more importantly, for patient care.
1. The PFA Revolution
The 100% success rate in the REAL PULSE study is likely to accelerate the global adoption of pulsed field ablation. By demonstrating that PFA can be performed with minimal risk of collateral damage, Medtronic is encouraging a shift away from older radiofrequency and cryoablation techniques that rely on thermal energy, which carries a higher risk of nerve and tissue damage.
2. Efficiency and Workflow
The Sphere-9 catheter’s ability to combine mapping and ablation reduces the need for "catheter exchange," a time-consuming part of cardiac procedures. By shortening procedural times, hospitals can increase their throughput, reducing wait times for patients and lowering the overall cost of care—a key metric for modern healthcare systems.
3. Broadening the Scope of Treatment
The success of the Sphere-9 in treating both AFib and VT indicates that the future of cardiac ablation lies in "all-in-one" systems. Instead of having separate specialized tools for different arrhythmias, clinicians are moving toward platforms that offer high-definition visibility and modular energy delivery, allowing them to treat more patients with a single, highly refined setup.
4. A New Standard for Registry Data
Medtronic’s commitment to transparent, large-scale registry reporting sets a standard that other medical device manufacturers will likely need to follow. As regulatory bodies and hospital administrators demand more proof of value, the "REAL PULSE/APEX" model of reporting will likely become the benchmark for how new technologies are introduced and monitored in the clinical market.
Conclusion
The data presented at APHRS 2026 confirms that Medtronic’s cardiac ablation portfolio has moved past its experimental phase and is now delivering high-performance, safe outcomes for thousands of patients. With the PulseSelect system proving its reliability in AFib and the Affera/Sphere-9 system demonstrating its versatility in both AFib and complex VT, the landscape of electrophysiology is undergoing a fundamental change.
As the industry looks toward 2027 and beyond, the focus will likely remain on long-term outcomes and the further integration of these technologies into standard clinical pathways. For patients suffering from the debilitating effects of cardiac arrhythmias, the convergence of high-definition mapping and tissue-selective ablation energy offers a promising and safer path to recovery.
About the Author
